C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
CCCC 11.05.2024
Drug:CFT7455 Cemsidomide
Diseases:Multiple Myeloma
Diseases:Non-Hodgkin’s Lymphoma
Date of Upcoming Event:2024-12-07
Name of Upcoming Event:ASH Annual Meeting
About Gravity Analytica
Recent News
- 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
- 01.14.2025 - C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
- 01.08.2025 - C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Recent Filings
C4T to Host Webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET)
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that two abstracts from the ongoing Phase 1/2 trial of cemsidomide have been accepted for presentation at the ASH Annual Meeting taking place from December 7 – 10, 2024 in San Diego, California. Non-Hodgkin’s lymphoma (NHL) data will be shared as an oral presentation and multiple myeloma (MM) data will be shared as a poster presentation. The abstracts are available online on the ASH Annual Meetingwebsite.
The presentations on December 8that the ASH Annual Meeting will include updated data compared to the abstracts.
NHL Oral Presentation Details:
Title:Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC®Degrader, in Patients with Non-Hodgkin’s LymphomaFormat: Oral (10-minute presentation, followed by a 5-minute discussion)Session:T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in T Cell LymphomasSession Date:Sunday, December 8, 2024Presentation Time:10:30 AM PT (1:30 PM ET)Location:San Diego Convention Center, Ballroom 20CD
MM Poster Presentation Details:
Title:Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC®Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaFormat: Poster presentationSession:Multiple Myeloma: Pharmacologic Therapies: Poster IISession Date:Sunday, December 8, 2024Presentation Time:6:00 PM - 8:00 PM PT (9 PM – 11 PM ET)Location:San Diego Convention Center, Halls G-HPublication Number:3366
C4T Investor Webcast
C4T will host a webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET). A live webcast of the event will be available usingthis linkor under the “Events & Presentations” page of the Investors section on the company’s website atwww.c4therapeutics.com. A replay of the webcast will be archived and available following the event.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO®platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visitwww.c4therapeutics.com.
About Cemsidomide
Cemsidomide is an orally bioavailable MonoDAC®degrader designed to be highly potent and selective against its intended targets of Ikaros (IKZF1) and Aiolos (IKZF3) and overcome shortcomings of currently approved therapies to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). Cemsidomide is currently in a Phase 1 dose escalation study in MM and NHL. Initial clinical data show cemsidomide is well-tolerated, demonstrates anti-myeloma activity and displays evidence of immunomodulatory effects. More information about this trial may be accessed atwww.clinicaltrials.gov(identifier: NCT04756726).
Contacts:
Investors:Courtney SolbergSenior Manager, Investor RelationsCSolberg@c4therapeutics.com
Media:Loraine SpreenSenior Director, Corporate Communications & Patient AdvocacyLSpreen@c4therapeutics.com
